{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:25:17Z","timestamp":1773923117239,"version":"3.50.1"},"reference-count":27,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100019383","name":"cipla","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Cardiovascular Disease"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Heart failure (HF) remains a major public health challenge in India, with a need for effective and well-tolerated therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The RESTORE-HF study evaluated the real-world effectiveness and safety of torsemide-spironolactone fixed-dose combination (FDC) in Indian patients with HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Prospective, multicenter, observational study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study was conducted across 101 sites in India. Patients aged 18\u201375 years with HF with reduced ejection fraction and signs of congestion were enrolled and initiated on the torsemide-spironolactone FDC. Participants were followed over 3 weeks from baseline. The primary objective was the change in body weight. Secondary endpoints included changes in New York Heart Association (NYHA) functional class, edema, occurrence of adverse events (AEs), and physician and patient assessments of efficacy and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 1841 patients screened, 1752 were enrolled, and 1520 completed the study. The mean (SD) age of participants was 58.61 (9.45) years, of whom 61.05% were male. The study showed a significant reduction in mean body weight was observed from 75.54 kg at baseline to 73.13 kg at week 3 (mean difference: 2.41 kg;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.0001). Additionally, an improvement in NYHA functional class and edema was observed over 3 weeks from baseline. Overall, 22.11% patients achieved no-edema stage. Only three mild AEs related to loose stools were reported, and no serious AEs or deaths occurred. Over 98% of physicians and patients rated the therapy favorably.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The RESTORE-HF study demonstrated that the torsemide-spironolactone FDC may be associated with a mean body weight reduction of 2.41 kg and may be generally well-tolerated in Indian heart failure patients. Furthermore, the FDC may be linked to significant symptomatic improvement over 3 weeks in real-world clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17539447261430243","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:02:04Z","timestamp":1773766924000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness and safety of torsemide and spironolactone fixed dose combination in Indian heart failure patients (RESTORE-HF study): a prospective, multicenter, observational study"],"prefix":"10.1177","volume":"20","author":[{"given":"Chandrashekhar K.","family":"Ponde","sequence":"first","affiliation":[{"name":"Department of Cardiology, P. D. Hinduja Hospital, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devanu","family":"Ghosh Roy","sequence":"additional","affiliation":[{"name":"Peerless Hospital, Kolkata, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uday","family":"Jadav","sequence":"additional","affiliation":[{"name":"MGM New Bombay Hospital, Vashi, New Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Mohanty","sequence":"additional","affiliation":[{"name":"Sir Ganga Ram Hospital, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karan","family":"Dang","sequence":"additional","affiliation":[{"name":"Paras Hospital, Panchkula, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Febin","family":"Francis","sequence":"additional","affiliation":[{"name":"Medical Affairs, Cipla Ltd, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin","family":"Zalte","sequence":"additional","affiliation":[{"name":"Medical Affairs, Cipla Ltd, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9207-5605","authenticated-orcid":false,"given":"Amarnath","family":"Sugumaran","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Cipla Ltd, 289, Bellasis Road, Mumbai Central, Mumbai, Maharashtra 400008, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandesh","family":"Sawant","sequence":"additional","affiliation":[{"name":"Medical Affairs, Cipla Ltd, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senthilnathan","family":"Mohanasundaram","sequence":"additional","affiliation":[{"name":"Medical Affairs, Cipla Ltd, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac013"},{"issue":"5","key":"e_1_3_4_3_2","first-page":"283","article-title":"Heart failure: epidemiology and prevention in India","volume":"23","author":"Huffman MD","year":"2010","unstructured":"Huffman MD, Prabhakaran D. Heart failure: epidemiology and prevention in India. Natl Med J India 2010; 23(5): 283\u2013288.","journal-title":"Natl Med J India"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01887-4"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2022.069"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.59556\/japi.72.0678"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024661"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2023.11.111"},{"issue":"2","key":"e_1_3_4_10_2","first-page":"75","article-title":"Baseline characteristics of Indian heart failure patients using torsemide and spironolactone fixed-dose combination: Insights from the RESTORE-HF real-world evidence study","volume":"3","author":"Ponde CK","year":"2025","unstructured":"Ponde CK, Roy DG, Jadhav U, et al. Baseline characteristics of Indian heart failure patients using torsemide and spironolactone fixed-dose combination: Insights from the RESTORE-HF real-world evidence study. Heart Fail J India 2025; 3(2): 75\u201381.","journal-title":"Heart Fail J India"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","unstructured":"Von Elm E Altman DG Egger M et al. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: checklist for cohort studies https:\/\/www.equator-network.org\/wp-content\/uploads\/2015\/10\/STROBE_checklist_v4_cohort.pdf (2007 accessed 22 November 2025).","DOI":"10.1371\/journal.pmed.0040296"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.4103\/2395-5414.182988"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2021.04.017"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2020.10.012"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.23924"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14255"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0379-7"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"e_1_3_4_19_2","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145: e895\u2013e1032.","journal-title":"Circulation"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.59556\/japi.72.0672"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02855-3"},{"key":"e_1_3_4_22_2","unstructured":"Pfizer Inc. Aldactone Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/012151s075lbl.pdf (2018 accessed 21 April 2025)."},{"key":"e_1_3_4_23_2","unstructured":"Pfizer Inc. Aldactone https:\/\/www.pfizermedicalinformation.com\/aldactone\/dosage-admin (2025 accessed 21 April 2025)."},{"issue":"1","key":"e_1_3_4_24_2","first-page":"31","article-title":"Spironolactone + torsemide induced Stevens-Johnson syndrome","volume":"1","author":"Patel A","year":"2021","unstructured":"Patel A, Trivedi N, Gor A. Spironolactone + torsemide induced Stevens-Johnson syndrome. J Heal Sci Prof Educ 2021; 1(1): 31\u201333.","journal-title":"J Heal Sci Prof Educ"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.53411\/jpadr.2020.1.1.5"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.4103\/0970-258X.262913"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2018-313492"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31824-9"}],"container-title":["Therapeutic Advances in Cardiovascular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17539447261430243","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17539447261430243","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17539447261430243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:16:24Z","timestamp":1773908184000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17539447261430243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":27,"alternative-id":["10.1177\/17539447261430243"],"URL":"https:\/\/doi.org\/10.1177\/17539447261430243","relation":{},"ISSN":["1753-9447","1753-9455"],"issn-type":[{"value":"1753-9447","type":"print"},{"value":"1753-9455","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"17539447261430243"}}